PMID: 25790697Jan 1, 2014Paper

The level of neurospecific proteins in patients with type 1 diabetes mellitus and cognitive disorders

Klinicheskaia meditsina
M V NovoselovaN G Zhukova

Abstract

Type I diabetes mellitus (DM1) is a widespread metabolic disease ofsocial significance due to early disability in youngpatients and reduced life expectancy. One of the DMI complications is CNS lesions resulting in cognitive dysfunction mediated through metabolic disorders. This condition can be partly or completely reversed if diagnosed and treated'at an early stage. The aim of this study was to determine the level ofneurospecific proteins in 58 patients aged 16-30years with type I diabetes mellitus and cognitive disorders in comparison with 29 healthy controls of simnilar age. All the participants underwent neuropsychological testing based on the Montreal scale for rapid screening of cognitive disorders (MoCA-test). Protein S100, glial fibrillary acidic protein, and myelin basic protein served as early markers of cognitive dysfunction. The study revealed an enhanced level of neurospecific proteins that correlated with hyperglycemia and cognitive deficit (MoCA score 26).

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.